HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)
Latest Information Update: 23 Mar 2022
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions
- Sponsors AbbVie
- 19 Mar 2022 Results assessing the safety and effectiveness of up to 52 weeks of adalimumab treatment, published in the Ophthalmology and Therapy
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.
- 29 Oct 2018 Planned End Date changed from 31 May 2020 to 27 Sep 2020.